Table 2.
Summary of any grade treatment-related AEs reported in at least 10% of patients.
| All patients (n = 39) n (%) | |||
|---|---|---|---|
| Adverse events | Grade 1–2 | Grades 3–4 | Total |
| Diarrhea | 21 (54) | 9 (23) | 30 (77) |
| Fatigue | 21 (54) | 2 (5) | 23 (59) |
| Nausea | 18 (46) | 1 (3) | 19 (49) |
| Acneiform rash | 16 (41) | 3 (8) | 19 (49) |
| Photosensitivity | 13 (33) | 1 (3) | 14 (36) |
| Maculopapular rash | 11 (28) | 2 (5) | 13 (33) |
| Arthralgia | 13 (33) | 0 (0) | 13 (33) |
| Vomiting | 9 (23) | 2 (5) | 11 (28) |
| Fever | 7 (18) | 1 (3) | 8 (21) |
| AST elevation | 7 (18) | 1 (3) | 8 (21) |
| ALT elevation | 6 (15) | 1 (3) | 7 (18) |
| Pruritus | 4 (10) | 1 (3) | 5 (13) |
| Mucositis oral | 4 (10) | 1 (3) | 5 (13) |
| Anemia | 3 (8) | 1 (3) | 4 (10) |
| ALP elevation | 3 (8) | 1 (3) | 4 (10) |
Abbreviations: ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase.